Periodic Reporting for period 1 - NanoLymphoma (Novel therapeutic platform for aggressive lymphoma: NanoLymphoma)

The problem: Poor clinical outcome of patients with aggressive B-cell lymphoma after immunotherapy. Immunotherapy using antibodies targeting the cell surface has led to important clinical advances in patients with cancer, exemplified by CD20-antibodies that are first-line...